Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough
Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout, Carine Rouanet, Amena Ben Younes, Colette Creusy, Jacquelyn Engle, William E Goldman, Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout, Carine Rouanet, Amena Ben Younes, Colette Creusy, Jacquelyn Engle, William E Goldman, Camille Locht
Abstract
Pertussis is still among the principal causes of death worldwide, and its incidence is increasing even in countries with high vaccine coverage. Although all age groups are susceptible, it is most severe in infants too young to be protected by currently available vaccines. To induce strong protective immunity in neonates, we have developed BPZE1, a live attenuated Bordetella pertussis strain to be given as a single-dose nasal vaccine in early life. BPZE1 was developed by the genetic inactivation or removal of three major toxins. In mice, BPZE1 was highly attenuated, yet able to colonize the respiratory tract and to induce strong protective immunity after a single nasal administration. Protection against B. pertussis was comparable to that induced by two injections of acellular vaccine (aPV) in adult mice, but was significantly better than two administrations of aPV in infant mice. Moreover, BPZE1 protected against Bordetella parapertussis infection, whereas aPV did not. BPZE1 is thus an attractive vaccine candidate to protect against whooping cough by nasal, needle-free administration early in life, possibly at birth.
Conflict of interest statement
Competing interests. The authors have declared that no competing interests exist.
Figures
References
- World Health Organization [WHO] The world health report 2004—Changing history. Geneva: WHO; 2004. Available: . Accessed 31 May 2006.
- Das P. Whooping cough makes global comeback. Lancet Infect Dis. 2002;2:322.
- Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J. 2005;24:S10–S18.
- Centers for Disease Control and Prevention. Pertussis. Available: . Accessed 31 May 2006.
- Wirsing von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis. 2002;2:744–750.
- Lewis DB, Yu CC, Meyer J, English BK, Kahn SJ, et al. Cellular and molecular mechanisms for reduced interleukin-4 and interferon-γ production by neonatal T cells. J Clin Invest. 1991;87:194–202.
- Siegrist CA. Neonatal and early life vaccinology. Vaccine. 2001;19:3331–3346.
- Mills KHG. Immunity to Bordetella pertussis . Microbes Infect. 2001;3:655–677.
- Lewis DB, Larsen A, Wilson CB. Reduced interferon-γ mRNA levels in human neonates. J Exp Med. 1986;163:1018–1023.
- Ausiello CM, Urbani F, La Sala A, Lande R, Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination in infants with whole-cell or acellular pertussis vaccines. Infect Immun. 1997;65:2168–2174.
- Wirsing von König CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: Frequency of transmission after household exposure. Lancet. 1995;346:1326–1329.
- Mascart F, Verscheure V, Malfroot A, Hainaut M, Piérard D, et al. Bordetella pertussis infection in 2-months-old infants promotes Type 1 T cell responses. J Immunol. 2003;170:1504–1509.
- Locht C, Antoine R, Jacob-Dubuisson F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Curr Opin Microbiol. 2001;4:82–89.
- Heiss LN, Flak TA, Lancaster JR, McDaniel ML, Goldman WE. Nitric oxide mediates Bordetella pertussis tracheal cytotoxin damage to the respiratory epithelium. Infect Agents Dis. 1993;2:173–177.
- Goldman WE, Cookson BT. Structure and functions of the Bordetella tracheal cytotoxin. Tokai J Exp Clin Med. 1988;13((Suppl)):187–191.
- Locht C, Antoine R. Bordetella pertussis protein toxins. In: Alouf JE, Freer JH, editors. Comprehensive sourcebook of bacterial protein toxins. San Diego: Academic Press; 1999. pp. 130–146.
- Guiso N, Capiau C, Carletti G, Poolman J, Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine. 1999;17:2366–2376.
- Mills KH, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis . Infect Immun. 1998;66:594–602.
- Roduit C, Bozzotti P, Mielcarek N, Lambert PH, Del Giudice G, et al. Immunogenicity and protective efficacy of neonatal immunization against Bordetella pertussis in a murine model: Evidence for early control of Pertussis. Infect Immun. 2002;70:3521–3528.
- He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA. 1998;280:635–637.
- Watanabe M, Nagai M. Whooping cough due to Bordetella parapertussis: An unresolved problem. Expert Rev Anti Infect Ther. 2004;2:447–454.
- Mastrantonio P, Stefanelli P, Giuliano M, Herrera Rojas Y, Ciofi degli Atti M, et al. Bordetella parapertussis infection in children: Epidemiology, clinical symptoms, and molecular characteristics of isolates. J Clin Microbiol. 1998;36:999–1002.
- Liese JG, Renner C, Stojanov S, Belohradsky BH, Munich Vaccine Study Group. Clinical and epidemiological picture of B pertussis and B parapertussis infections after introduction of acellular pertussis vaccines. Arch Dis Child. 2003;88:684–687.
- Watanabe M, Nagai M. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect Immun. 2001;69:6981–6986.
- Locht C, Bertin P, Menozzi FD, Renauld G. The filamentous haemagglutinin, a multifaceted adhesin produced by virulent Bordetella spp. Mol Microbiol. 1993;9:653–660.
- Huang CC, Chen PM, Kuo JK, Chui WH, Lin ST, et al. Experimental whooping cough. N Engl J Med. 1962;266:105–111.
- Bey RF, Shade FJ, Goodnow RA, Johnson RC. Intranasal vaccination of dogs with live avirulent Bordetella bronchiseptica: Correlation of serum aggutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. Am J Vet Res. 1981;42:1130–1132.
- De Jong MF. Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine. Vet Q. 1987;9:123–133.
- Hoiseth SK, Stocker BAD. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981;291:238–239.
- Roberts M, Maskell D, Novotny P, Dougan G. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect Immun. 1990;58:732–739.
- Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis. 2003;14:196–198.
- Robbins JB, Schneerson R, Trollfors B, Sato H, Sato Y, et al. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis. 2005;191:81–88.
- Holt PG, Clough JB, Holt BJ, Baron-Hay MJU, Rose AH, et al. Genetic “risk” for atopy is associated with delayed postnatal maturation of T-cell competence. Clin Exp Allergy. 1992;22:1093–1099.
- Favre D, Viret JF. Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation. Vaccine. 2005;24:3856–3864.
- Cohn SE, Knorr KL, Gilligan PH, Smiley ML, Weber DJ. Pertussis is rare in human immunodeficiency virus disease. Am Rev Respir Dis. 1993;147:411–413.
- Porter JF, Wardlaw AC. Long-term survival of Bordetella bronchiseptica in lakewater and in buffered saline without added nutrients. FEMS Microbiol Lett. 1993;110:33–36.
- Linnemann CC, Jr, Bass JW, Smith MHD. The carrier state in pertussis. Am J Epidemiol. 1968;88:422–427.
- Parton R, Hall E, Wardlaw AC. Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis. J Med Microbiol. 1994;40:307–312.
- Mielcarek N, Alonso S, Locht C. Nasal vaccination using live bacterial vectors. Adv Drug Del Rev. 2001;51:55–69.
- Menozzi FD, Mutombo R, Renauld G, Gantiez C, Hannah JH, et al. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis . Infect Immun. 1994;62:769–778.
- Imaizumi A, Suzuki Y, Ono S, Sato H, Sato Y. Effect of heptakis (2,6-O-dimethyl)-beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis . Infect Immun. 1983;41:1138–1143.
- Cookson BT, Cho H-L, Herwaldt LA, Goldman WE. Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis . Infect Immun. 1989;57:2223–2229.
- Alonso S, Pethe K, Mielcarek N, Raze D, Locht C. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection. Infect Immun. 2001;69:6038–6043.
- Collyn F, Lety MA, Nair S, Escuyer V, Ben Younes A, et al. Yersinia pseudotuberculosis harbors a type IV pilus gene cluster that contributes to pathogenicity. Infect Immun. 2002;70:6196–6205.
- Mielcarek N, Cornette J, Schacht AM, Pierce RJ, Locht C, et al. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen. Infect Immun. 1997;65:544–550.
- Locht C, Geoffroy MC, Renauld G. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. EMBO J. 1992;11:3175–3183.
- Sekura RD, Fish F, Manclark CR, Meade B, Zhang YL. Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem. 1983;258:14647–14651.
- Antoine R, Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun. 1990;58:1518–1526.
- Menozzi FD, Gantiez C, Locht C. Interaction of the Bordetella pertussis filamentous haemagglutinin with heparin. FEMS Microbiol Lett. 1991;62:59–64.
Source: PubMed